Daiichi Sankyo acquires Plexxikon for $805-935M in cash: http://finance.yahoo.com/news/Plexxikon-Inc-to-Join-Daiichi-prnews-4205241039.html?x=0&.v=1 $130M is contingent on regulatory approval and launch of PLX4032 in metastatic melanoma (#msg-58950046).